Clinical Trial Update: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer [NA]

View source ↗

Summary

An ongoing SWOG trial (S1703) is evaluating serum tumor marker-directed disease monitoring in hormone receptor-positive, HER2-negative metastatic breast cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive | NA | Status: RECRUITING